Kevin R Kelly
University of Southern California · City of Hope Comprehensive Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kevin R Kelly as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:29 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05514990 · Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH TrialUniversity of Southern California · active not recruiting · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
- Ph1NCT04190550 · Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid LeukemiaNational Cancer Institute (NCI) · active not recruiting · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · principal investigator
- Ph1NCT03041688 · Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid LeukemiaNational Cancer Institute (NCI) · active not recruiting · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Research Training and Education CoordinationP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Josh Neman-Ebrahim · fiscal years 2001 to 2026Named on NCT05514990
- Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTNUM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov, PRIMO N. LARA, HEINZ JOSEF LENZ · fiscal years 2014 to 2026Named on NCT04190550, NCT03041688
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 10:29 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.Clin Cancer Res · 2016316 citationsRCR 9.3
- Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.Blood · 202387 citationsRCR 7.6
- Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.Haematologica · 201674 citationsRCR 2.1
- Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.Leuk Res · 202146 citationsRCR 2.3
- Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.Clin Lymphoma Myeloma Leuk · 202412 citationsRCR 1.6